BB Biotech AG

BION:SWX

BB Biotech AG

Actions
  • Price (CHF)38.45
  • Today's Change-0.600 / -1.54%
  • Shares traded55.62k
  • 1 Year change+3.36%
  • Beta1.1104
Data delayed at least 15 minutes, as of Nov 13 2024 13:32 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year BB Biotech AG had revenues fall -57.97% from 1.26m to 530.00k, though the company grew net income from a loss of 357.81m to a smaller loss of 206.61m.
Gross margin97.86%
Net profit margin46.32%
Operating margin46.35%
Return on assets4.99%
Return on equity5.64%
Return on investment5.64%
More ▼

Cash flow in CHFView more

In 2023, cash reserves at BB Biotech AG fell by 1.45m. However, the company earned 218.28m from its operations for a Cash Flow Margin of 41,184.15%. In addition the company used on investing activities and also paid 220.21m in financing cash flows.
Cash flow per share--
Price/Cash flow per share--
Book value per share40.66
Tangible book value per share40.66
More ▼

Balance sheet in CHFView more

BB Biotech AG has a Debt to Total Capital ratio of 10.96%.
Current ratio9.04
Quick ratio--
Total debt/total equity0.1231
Total debt/total capital0.1096
More ▼

Growth rates in CHF

Year on year, growth in dividends per share fell -29.82% while earnings per share excluding extraordinary items rose 42.08%. Additionally, five year annualized dividend per share growth is in-line with the industry average relative to its peers.
Div yield(5 year avg)4.98%
Div growth rate (5 year)-8.09%
Payout ratio (TTM)88.39%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
135.81
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.